Allison Betof Warner

Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy

Stanford University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Allison Betof Warner is an Assistant Professor and the Director of Melanoma Medical Oncology as well as the Director of Solid Tumor Cellular Therapy at Stanford University, USA. Her research focuses on melanoma and includes recent work on high-dose interleukin-2, adoptive cell therapy, and tumor-infiltrating lymphocyte therapy. She has published extensively on the dynamic tumor immune microenvironment and the management of immune-related adverse events in melanoma treatments.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

UNITED KINGDOM

View details

Giao Phan

University of Connecticut Health Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Allison Betof Warner

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy

The Clinical TIL Experience in Melanoma: Past, Present, Future

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions

CD4+ TIL to the Rescue of Anti–PD-1 Failure by Targeting MHC-II

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

The future of cancer immunotherapy: microenvironment-targeting combinations

Collaborators (6)

Michael Charles Lowe

Jacob Choi

Maria Martinez-Lage

Yevgeniy Semenov

Pippa Corrie

Giao Phan

Make your next move.